Buy & Sell Corsair Gaming Inc (CRSR) – Corsair Gaming Inc Price Today
Aura AI Summary
Key Stats
- $843.30MMarket Cap
- TechnologySector
- -23.42%3M Drawdown
- $913.00MEnterprise Value
- -Dividend Yield
- 26 daysTypical Hold Time
Corsair Gaming Inc (CRSR) is currently valued at a market capitalization of $843.30M, with an enterprise value of $913.00M. Over the past 52 weeks, Corsair Gaming Inc has traded between a low of $4.58 and a high of $9.76, highlighting its annual price range. Over the past three months, Corsair Gaming Inc has recorded a drawdown of -23.42%, reflecting recent price volatility. On average, investors hold Corsair Gaming Inc for approximately 26 days, indicating typical investor behavior on the platform.
About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Most Recent News
BTS Group to present Q1 2026 interim report on May 21 with live Q&A session
BTS Group AB, a global consultancy specializing in strategy execution and people development, will present its Q1 2026 interim report on May 21 at 08:00 am CEST. The presentation, led by CEO Jessica Skon and moderated by analyst Johan Sundén, will be...
Chinese crude oil imports drop 20% in April, easing pressure on global oil prices.
China's crude oil imports fell 20% month-over-month in April to 8.2 million barrels per day, the lowest in two years and nearly 30% below pre-war levels. This significant drop, equivalent to Japan's total daily oil consumption, may help ease the upwa...
Anaveon presents positive ANV600 cancer drug data at ASCO 2026, seeks partners for oncology assets.
Anaveon announced positive Phase 1 clinical data for its cancer drug ANV600, showing safety and early tumor shrinkage benefits, at the ASCO 2026 meeting. ANV600 targets PD-1 to boost immune response against tumors, including in resistant cases, and i...
